Global proteomic analysis of the oocyst/sporozoite of Toxoplasma gondii reveals commitment to a host-independent lifestyle

Alessia Possenti†, Federica Fratini†, Luca Fantozzi‡, Edoardo Pozio†, Jitender P Dubey§, Marta Ponzi†, Elisabetta Pizzi† and Furio Spano†*

Abstract

Background: Toxoplasmosis is caused by the apicomplexan parasite Toxoplasma gondii and can be acquired either congenitally or via the oral route. In the latter case, transmission is mediated by two distinct invasive stages, i.e., bradyzoites residing in tissue cysts or sporozoites contained in environmentally resistant oocysts shed by felids in their feces. The oocyst plays a central epidemiological role, yet this stage has been scarcely investigated at the molecular level and the knowledge of its expressed proteome is very limited.

Results: Using one-dimensional gel electrophoresis coupled to liquid chromatography-linked tandem mass spectrometry, we analysed total or fractionated protein extracts of partially sporulated T. gondii oocysts, producing a dataset of 1304 non redundant proteins (~18% of the total predicted proteome), ~59% of which were classified according to the MIPS functional catalogue database. Notably, the comparison of the oocyst dataset with the extensively covered proteome of T. gondii tachyzoite, the invasive stage responsible for the clinical signs of toxoplasmosis, identified 154 putative oocyst/sporozoite-specific proteins, some of which were validated by Western blot. The analysis of this protein subset showed that, compared to tachyzoites, oocysts have a greater capability of de novo amino acid biosynthesis and are well equipped to fuel the Krebs cycle with the acetyl-CoA generated through fatty acid β-oxidation and the degradation of branched amino acids.

Conclusions: The study reported herein significantly expanded our knowledge of the proteome expressed by the oocyst/sporozoite of T. gondii, shedding light on a stage-specific subset of proteins whose functional profile is consistent with the adaptation of T. gondii oocysts to the nutrient-poor and stressing extracellular environment.

Keywords: Toxoplasma gondii, Oocyst, Sporozoite, Proteome, Metabolism, Energy production, Host cell invasion, Oocyst-specific proteins

Background
The obligate intracellular parasite Toxoplasma gondii is a protozoan of the Phylum Apicomplexa highly prevalent in humans and animals worldwide [1]. Its clinical relevance is mainly due to potential congenital transmission to the fetus by seronegative women, causing intrauterine death or severe sequelae in the newborn [2] and adult life [3]. Furthermore, reactivation of latent infections in immunocompromised subjects can lead to life-threatening encephalitis. The complex life cycle of T. gondii includes three infectious stages, the tachyzoite, the bradyzoite and the sporozoite [4]. The rapidly dividing tachyzoite is responsible for the clinical signs of toxoplasmosis, as it disseminates the infection to virtually all organs and tissues of the host and can reach the fetus transplacentally. However, the major role in disease transmission is played by the oral ingestion of either bradyzoites encysted in the tissues of chronically infected hosts or sporozoites contained in the oocyst. This highly resistant environmental stage is the result of sexual reproduction, which occurs in the intestinal epithelium of cats and virtually all species of felids and...
culminates in the fecal shedding of unsporulated oocysts [5]. In the external environment, oocysts undergo sporogony [6] and develop two ellipsoidal sporocysts containing four infectious sporozoites each, which can survive in moist soil or water for months to years [1].

Despite its crucial epidemiological role, the sporozoite is the less characterized at the molecular level among the infectious stages of *T. gondii*, mostly due to the difficulty in producing and handling oocysts. The existence of oocyst/sporozoite-specific proteins was first documented nearly thirty years ago by serological and biochemical methods [7,8], yet no stage-specific protein was identified until 2004, when Radke and colleagues characterized the major sporozoite surface antigen SRS28 (SporoSAG) [9]. Subsequently, we reported on the cloning and immunolocalization of the cysteine-rich oocyst wall proteins TgOWP1, TgOWP2 and TgOWP3 [10], whereas Hill et al. [11] employed a proteomic-based approach to demonstrate that sporozoites specifically express the immunogenic embryogenesis-related protein (TgERP). In recent years, several groups applied different high-throughput proteomic techniques to the study of the tachyzoite of *Toxoplasma gondii*. The analysis of whole [12,13] or enriched [14-21] protein extracts provided an extensive coverage of the protein complement expressed by this parasite stage, with >5000 distinct proteins identified, which account for ~73% of the global predicted proteome. Following large-scale proteomic analyses of the oocyst stage of two other apicomplexans, i.e., *Cryptosporidium parvum* [22,23] and *Eimeria tenella* [24], very recently Fritz and co-workers published a proteomic study of fully sporulated oocysts of the *T. gondii* strain M4 (genotype II) [25].

Using one-dimensional (1-D) gel electrophoresis coupled to liquid chromatography (LC)-linked tandem mass spectrometry (MS/MS), the authors analysed protein extracts from either oocyst wall or sporocyst/sporozoite fractions and produced a first proteomic chart of 1031 individual proteins, including small subsets of molecules possibly implicated in oocyst environmental resistance and moving junction formation.

In the present work, we report on the proteomic analysis of partially sporulated oocysts of *T. gondii* belonging to the genotype III strain VEG. The identification of 1304 non-redundant proteins increased significantly the coverage of the oocyst/sporozoite proteome and allowed to expand our knowledge of developmentally regulated protein expression in *T. gondii*, highlighting differences between the repertoires of metabolic enzymes expressed by the oocyst/sporozoite and tachyzoite stage.

**Results**

**Analysis of the oocyst/sporozoite proteome of *T. gondii* by one-dimensional electrophoresis gel LC MS/MS**

To shed light on the expressed proteome of the oocyst/sporozoite of *Toxoplasma gondii*, total proteins were extracted from partially sporulated oocysts of the type III strain VEG [1] and analysed by one-dimensional gel electrophoresis LC-MS/MS in three independent experiments (Additional file 1). The oocyst batch used throughout the study consisted of approximately 60% fully sporulated and 40% non sporulated oocysts, as estimated by light microscopy observation.

Peptide sequences generated from raw mass spectra were initially matched against the release 5.1 of ToxoDB (http://www.toxodb.org/), yielding 6114 individual protein identifications. The entire dataset was successively updated on the release 7.1 of the database. After removal of redundancies, mostly due to multiple identifications of the same gene in different parasite reference strains, experiments 1, 2 and 3 allowed the identification of 1083, 1082 and 1314 *T. gondii* proteins, respectively (Figure 1), with overlaps between different experiments of between 65% and 83%. Approximately 47% of the proteins (758) were identified in all experiments, whereas varying numbers were detected uniquely in experiment 1 (115), 2 (77) or 3 (317) (Figure 1). The three independent analyses yielded a combined dataset of 1615 non-redundant oocyst/sporozoite proteins (Additional file 2) accounting for ~22% of the ToxoDB predicted proteome, which, according to a recent estimate, consists of ~7300 proteins [26]. According to ToxoDB annotations, 25% of the 1615 proteins identified...
in this study contain a signal peptide and 18% possess at least one transmembrane domain, two structural features occurring in very similar proportions in the predicted proteome of *T. gondii*, i.e., 21% and 18%, respectively. Approximately 38% of the oocyst/sporozoite identifications correspond to “hypothetical” proteins, which otherwise account for nearly 60% of the entire predicted proteome.

**Functional analysis of the protein dataset**

Of 1615 proteins, 311 (19%) were identified with a single peptide in one experiment and were excluded from functional analyses. The remaining 1304 proteins were assigned a subcellular localization (Figure 2A) combining the Gene Ontology (GO) cellular component predictions available in ToxoDB, with the results produced by the general subcellular predictor WoLF PSORT. Putative mitochondrial and apicoplast localizations were further assessed using the PlasMit and PATS predictors, respectively. Proteins with cytoplasmic (24%), nuclear (21%) and mitochondrial (14%) localizations were highly represented, whereas nearly one-third of the molecules identified were associated with parasite’s secretory routes, including those assigned to extracellular locations (14%), the plasmamembrane (10%) and the apical complex (4%). The latter category included 47 micronemal and rhoptry proteins, many of which have been thoroughly characterized in recent years.

Of 1304 proteins, 767 (~59%) were assigned a functional category according to the MIPS functional catalogue database (FunCatDB) (Figure 2B). The vast majority of these proteins were classified using the GO biological process annotations of ToxoDB, which cover only 25% of the
predicted proteome. A small fraction of the proteins involved in metabolic processes was identified using the KEGG Pathway database (http://www.genome.jp/kegg/), whereas approximately 80 molecules were assigned to a MIPS category based on sequence similarities with functionally characterized T. gondii paralogs, independent BLAST homology searches or exploiting information on subcellular localization contained in recent literature. The most numerous functional categories included proteins involved in protein fate (164), metabolism (140), protein synthesis (101), cell rescue, defence and virulence (99) and cellular transport (97).

The comparison of the VEG oocyst proteins with the expressed tachyzoite proteome provided a global, yet not exhaustive, view of the different protein repertoires expected to play a role in host cell invasion by T. gondii sporozoites. Our dataset comprises 9 proteins belonging to the SRS superfamily [27], which consists of >100 GPI-anchored surface ligands related to SRS29B (SAG1), an immunodominant protein highly expressed on tachyzoites. We also detected 16 proteins (MICs) localized to the micronemes, the apical secretory organelles involved in parasite motility and/or invasion, and several invasion-related molecules residing in a second type of apical organelle, i.e., the club-shaped rhoptry [28]. These included 11 rhoptry neck proteins (RONs), which are essential constituents of the moving junction [29,30], and 28 rhoptry bulb proteins (ROPs), which are secreted into the nascent parasitophorous vacuole (PV) or injected into the host cell cytoplasm, thus participating in the modification of the PV membrane or in the subversion of host cell transcription. The oocyst dataset included also 8 proteins localized to the dense granules (GRAs), which release their content into the vacuolar space in the late phases of invasion [31].

**Correlation between proteomic and transcriptional data**

To gain insight into the relationship between protein and mRNA expression [32], we matched the proteomic data generated in the present study with oocyst/sporozoite-specific transcriptional data available in ToxoDB 7.1 (Figure 3A). These included 1167 non-redundant ESTs from partially (999) or fully (250) sporulated oocysts,
1269 non-redundant sporozoite SAGE tags [33] and mRNA microarray data on 7114 T. gondii genes relative to M4 oocysts at various sporulation stages [34]. Using ToxoDB bioinformatic tools, we analysed the M4 microarray data to identify genes upregulated in day 0 (unsporulated) versus day 10 (fully sporulated) oocysts and vice versa. Excluding genes with a transcriptional fold increment <2, we found that 248 (19%) and 393 (30%) proteins out of 1304 were encoded by genes showing transcriptional upregulation in day 0 or day 10 oocysts, respectively (Figure 3B). At day 0, only 4.8% of upregulated genes exhibited a rise of mRNA levels greater than 10-fold, with a maximum increment of 18.6-fold, whereas the vast majority (74%) showed a transcriptional increase of only 2- to 5-fold. This unequal distribution may reflect the fact that a significant fraction of these genes have a transcriptional peak in developmental stages preceding the unsporulated oocyst, e.g., the macrogamete or the early zygote. Quite distinctly, ~41% of the genes upregulated in fully sporulated oocysts showed transcriptional increments higher than 10-fold, with 33 genes exhibiting fold increase values >100, e.g., the dense granule proteins GRA7 (933) and GRA1 (810), the microneme protein MIC11 (443) and the surface antigen SRS57 (367).

Based on the assignment to MIPS functional categories, the proteins encoded by genes upregulated in day 0 versus day 10 oocysts showed a higher relative abundance of molecules implicated in metabolism (16.5% versus 5.3%), cellular transport (12.5% versus 3.6%) and protein fate (15.3% versus 6.9%) (Figure 3C). On the other hand, genes upregulated at day 10 encoded higher proportions of molecules involved in protein synthesis (10.4% versus 4.8%) and in cell rescue, defence and virulence (15.0% versus 3.6%), with the latter group consisting mainly of proteins located in secretory organelles [35], i.e., the rhoptries (39), the micronemes (16) and the dense granules (8).

Putative oocyst/sporozoite-specific proteins (POSPs)
During the preparation of this manuscript, a considerable number of novel proteomic identifications was added to the release 7.1 of ToxoDB, including phosphoproteomic and total proteomic data on intracellular and extracellular tachyzoites [18,19] and the results of a global analysis of oocyst proteins fractionated into wall and sporocyst/sporozoite components [25]. Despite a marked cross-contamination of the analysed fractions, the latter approach led to the identification of 1031 proteins, 794 of which (77%) are represented in our dataset (Figure 4A). In addition, the proteins identified in the present study were filtered against the expressed tachyzoite proteome, which consisted of 5325 proteins resulting from the combination of global and subcellular proteomic data deposited in ToxoDB by various laboratories. As shown in Figure 4A, the oocyst/sporozoite dataset showed an overlap of ~88% with that of the tachyzoite and contained 154 proteins devoid of proteomic evidence in this stage. Given the numerous proteomic studies carried out on the tachyzoite and the consequent extensive coverage of its expressed proteome, these 154 unique proteins were likely to reflect developmentally regulated expression and were referred to as putative oocyst/sporozoite-specific proteins (POSPs) (Table 1). The stage specificity of three POSPs was tested by western blot using polyclonal antibodies raised against the LCCL domain-containing proteins TGME49_056040 and TGME49_067410 and the tyrosine-rich hypothetical protein TGME49_119890. As shown in Figure 4B, on protein lysates of partially sporulated VEG oocysts all antibodies yielded specific banding patterns compatible with the predicted molecular masses of the selected proteins, whereas no reactivity was observed on total tachyzoite extracts of the same parasite strain.

Functional role of molecules belonging to the POSP subset
Compared to the whole oocyst/sporozoite dataset, the POSP class exhibited a significant overrepresentation of hypothetical proteins (45% versus 35%), probably reflecting a defect in the annotation of oocyst/sporozoite proteins caused by the paucity of molecular studies on this parasite stage. Seventy-two out of 154 POSP (47%) were assigned a MIPS functional category, with proteins involved in metabolism (28) constituting the largest class, followed by molecules implicated in cell rescue, defence and virulence (17), energy production (12) and protein fate (11).

Central carbon metabolism
Our proteomic analysis showed that T. gondii oocysts express the entire enzymatic complements involved in glycolysis/glucoseogenesis and the tricarboxylic acid (TCA) cycle, the two main components of the central carbon metabolism of living organisms. Interestingly, VEG oocysts differed from tachyzoites for the abundant expression of two enolase isoforms, ENO1 and ENO2 [36]. So far, these two glycolytic enzymes were shown to be expressed in a mutually exclusive, stage-specific fashion in bradyzoites and tachyzoites, respectively, with only minimal amounts of ENO1 detected in tachyzoites by two proteomic studies [13,20]. While abundantly represented in our dataset, ENO1 was not identified in fully sporulated M4 oocysts [25], strongly suggesting that the expression of this bradyzoite-type enolase is developmentally regulated during oocyst maturation and is most likely specific to the unsporulated form. Also the TCA cycle comprises reactions catalyzed by two enzyme isoforms, e.g., isocitrate dehydrogenase (TGME49_066760, TGME49_113140) and succinate dehydrogenase (TGME49_015280, TGME49_015590), which were all detected by proteomics in both tachyzoites and VEG oocysts. In addition, our
analysis identified two differentially expressed isoforms of citrate synthase, TGME49_068890, detected also in tachyzoites and TGME49_003110, which is specific to the oocyst stage. Citrate synthase is a rate-determining enzyme converting oxaloacetate into citrate in the first step of the TCA cycle, therefore, the stage-specific expression of a second isoform may have important regulatory effects during oocyst development. Likewise, we found that the oocyst possesses two 50% identical isoforms of phosphoenolpyruvate carboxykinase, which provides a crucial link between the TCA cycle and gluconeogenesis by transforming oxaloacetate into phosphoenolpyruvate. One of the two isoforms, TGME49_089930, was uniquely identified in the oocyst and is encoded by a gene showing 30-fold transcriptional increase in unsporulated oocysts compared to tachyzoites. This enzyme might fuel the gluconeogenetic pathway and the eventual production of amylopectin [37], which represents an important energy source for sporulating oocysts and sporozoites.

Amino acid metabolism
The POSP subset included key enzymes for the synthesis of 6 non essential amino acids of *T. gondii*, i.e., proline (TGME49_069110), alanine (TGME49_115260, TGME49_003500), threonine (TGME49_016640), cysteine (TGME49_059180, TGME49_078910, TGME49_112930), lysine (TGME49_005420) and tyrosine (TGME49_087510, TGME49_012740). The two forms of alanine dehydrogenase (EC 1.4.1.1), which catalyses the unidirectional conversion of pyruvate into L-alanine, share 39% sequence identity and differ for their predicted subcellular localization, cytoplasmic for TGME49_115260 and mitochondrial for TGME49_003500. We detected also two 98% identical isoforms of tyrosine hydroxylase (TGME49_087510, TGME49_012740) possessing a bifunctional activity able to catabolize phenylalanine to tyrosine and tyrosine to 3,4-dihydroxy-L-phenylalanine (L-DOPA) [38]. The presence of these two enzymes in the oocyst stage may be important not only for de novo tyrosine synthesis, but also for the supply of L-DOPA, which was shown to be a component of the oocyst wall of *Eimeria maxima* [39], an avian coccidian parasite related to *T. gondii*. The oocyst differs from the tachyzoite also for the expression of three distinct enzymes involved in the biosynthesis of cysteine. This important amino acid can be produced either from L-serine, through the successive action of cystathionine β-synthase (TGME49_059180) and cystathionine β-lyase (TGME49_112930), or from O-acetylserine, through the fixation of inorganic sulphide by a plant/bacterial-like O-acetylserine (thiol) lyase (TGME49_078910). In contrast with previous views, current genomic data indicate that *T. gondii* is not a threonine auxotroph but has the potential to synthesize this amino acid using homoserine as precursor. Our data showed that a predicted enzyme linked to this pathway, homoserine kinase (TGME49_016640), is indeed expressed in the oocyst stage.
### Table 1 List of putative oocyst/sporozoite-specific proteins (POSPs) identified in this study

| Gene ID       | Protein name                                      | EC number | Biological process/molecular function | *Fold change of oocyst vs tachyzoite mRNA levels* | Protein probability |
|---------------|--------------------------------------------------|-----------|----------------------------------------|--------------------------------------------------|---------------------|
| TGME49_026300 | oxidoreductase, putative                         | 1.3.1.34  | fatty acid β-oxidation                  | 260 40 103                                        | 6.23E-11            |
| TGME49_034570 | peroxisomal multifunctional enzyme type 2, putative | 1.1.1.35  | fatty acid β-oxidation                  | 108 12 17                                         | 2.22E-16            |
| TGME49_042390 | enoyl-CoA hydratase/isomerase family protein, putative | 4.2.1.17  | fatty acid β-oxidation                  | 21 16 5                                          | 1.35E-12            |
| TGME49_047500 | acyl-coenzyme A oxidase, putative                | 1.3.3.6   | fatty acid β-oxidation                  | 92 37 49                                         | 6.76E-12            |
| TGME49_066270 | 2-methylbutyl-CoA dehydrogenase, putative        | 1.3.99    | fatty acid β-oxidation                  | 7 <2 <2                                          | 1.00E-30            |
| TGME49_115480 | tropomyosin 1 alpha chain, putative              | -        | regulation of actin mechanics           | 247 11 19                                        | 5.66E-06            |
| TGME49_031110 | citrate synthase, putative                       | 2.3.3.1   | TCA cycle                              | 35 5 7                                          | 6.32E-09            |
| TGME49_003340 | alkyl sulfatase, putative                        | 3.5.2.6   | -                                      | <2 <2 2                                          | 2.10E-05            |
| TGME49_003580 | NAD-binding domain-containing protein            | -        | -                                      | n.a. n.a. n.a.                                   | 4.73E-12            |
| TGME49_038200 | alpha/beta hydrolase fold domain-containing protein | -      | -                                      | 27 3 4                                          | 7.77E-15            |
| TGME49_065860 | nit protein 2, putative                          | -        | -                                      | 8 <2 2                                          | 2.14E-03            |
| TGME49_069120 | oxidoreductase, putative                         | 1.1.1.100 | -                                      | 183 61 125                                       | 4.44E-16            |
| TGME49_069400 | short chain dehydrogenase/reductase domain-containing protein | 1.1.1.100 | -                                      | 11 <2 <2                                        | 2.42E-07            |
| TGME49_106450 | short chain dehydrogenase family protein, putative | 1.1.1.100 | -                                      | <2 222 82                                        | 6.97E-05            |
| TGME49_111780 | alcohol dehydrogenase class III, putative        | 1.1.1.284 | -                                      | 4 <2 <2                                         | 4.61E-06            |
| TGME49_003500 | alanine dehydrogenase, putative                 | 1.4.1.1   | amino acid metabolism                  | 6 29 4                                          | 1.11E-15            |
| TGME49_005420 | aspartate-semialdehyde dehydrogenase, putative   | 1.2.1.11  | amino acid metabolism                  | 4 <2 <2                                         | 2.44E-08            |
| TGME49_016640 | homoserine kinase, putative                      | 2.7.39    | amino acid metabolism                  | 74 28 26                                        | 4.03E-12            |
| TGME49_059180 | cystathionine beta-synthase, putative            | 4.2.1.22  | amino acid metabolism                  | n.a. n.a. n.a.                                   | 8.37E-13            |
| TGME49_069110 | ornithine aminotransferase, putative             | 2.6.1.13  | amino acid metabolism                  | 394 123 247                                      | 2.54E-12            |
| TGME49_078900 | O-acetylserine (thiol) lyase, putative           | 2.5.1.47  | -                                      | 20 3 5                                          | 2.39E-10            |
| TGME49_120930 | cystathionine beta-lyase, putative               | 4.4.1.1   | amino acid metabolism                  | 23 2 3                                          | 2.90E-10            |
| TGME49_115260 | alanine dehydrogenase, putative                 | 1.4.1.1   | amino acid metabolism                  | 98 211 331                                       | 2.89E-14            |
| TGME49_019230 | acetoacetyl-CoA synthetase, putative             | 2.6.1.17  | butanoate metabolism                   | <2 <2 <2                                        | 4.97E-10            |
| TGME49_031900 | acyl-CoA dehydrogenase, putative                | 1.3.99.7  | fatty acid metabolism                  | 31 32 21                                        | 6.51E-11            |
| TGME49_003570 | acyltransferase, putative                        | 2.3.1.15  | glycerophospholipid metabolism         | 2 <2 <2                                         | 3.08E-13            |
| TGME49_010260 | glycerol-3-phosphate dehydrogenase, putative    | 1.1.18    | glycerophospholipid metabolism         | 188 14 32                                        | 6.84E-13            |
| TGME49_082230 | sulfate adenylytransferase-adenylyl sulfatase kinase, putative | 2.7.7.4 | purine metabolism                     | 52 5 10                                         | 7.38E-13            |
| TGME49_107030 | purine nucleoside phosphorylase                 | 2.4.2.3   | pyrimidine salvage pathway             | 12 2 3                                          | 1.11E-16            |
| Gene Name                              | Function                                                                 | Pathway/Cutaneous/Other         | FDR  |
|----------------------------------------|--------------------------------------------------------------------------|---------------------------------|------|
| **TGME49_003720** vitamin K epoxide reductase complex subunit 1, putative | terpenoid-quinone biosynthesis                                             | 1.63E-08                        | 9    |
| **TGME49_002140** methylglutaconyl-CoA hydratase, putative               | valine, leucine and isoleucine degradation                                | 1.02E-06                        | 5    |
| **TGME49_005430** isovaleryl-CoA dehydrogenase, putative                | valine, leucine and isoleucine degradation                                | 2.49E-10                        | 8    |
| **TGME49_015250** thiamin pyrophosphokinase, putative                    | vitamin biosynthesis                                                     | 1.03E-09                        | <2   |
| **TGME49_005660** F5/8 type C domain-containing protein (CCp1A)           | cell rescue, defence and virulence                                        | 6.35E-07                        | 24   |
| **TGME49_023480** thrombospondin type 1 domain-containing protein        | cell rescue, defence and virulence                                        | 1.11E-15                        | 343  |
| **TGME49_056040** LCCL domain-containing protein (CCpSB)                 | cell rescue, defence and virulence                                        | 2.51E-12                        | <2   |
| **TGME49_058370** Rhopty kinase family protein ROP28                     | cell rescue, defence and virulence                                        | 1.10E-10                        | 76   |
| **TGME49_063410** scavenger receptor protein TgSR2                       | cell rescue, defence and virulence                                        | 2.22E-15                        | 144  |
| **TGME49_064070** antigenic protein, putative (CCp1B)                   | cell rescue, defence and virulence                                        | 4.84E-09                        | <2   |
| **TGME49_067410** scavenger receptor protein TgSR1                       | cell rescue, defence and virulence                                        | 2.21E-08                        | 306  |
| **TGME49_027150** glutaredoxin, putative                                 | detoxification of oxygen radicals                                         | 6.84E-05                        | <2   |
| **TGME49_116190** superoxide dismutase, putative                        | detoxification of oxygen radicals                                         | 3.76E-12                        | 589  |
| **TGME49_009920** PAN domain-containing protein                          | host cell attachment/invasion                                             | 2.33E-14                        | 557  |
| **TGME49_032400** PAN domain-containing protein                          | host cell attachment/invasion                                             | 7.77E-15                        | 44   |
| **TGME49_038460** SRS22B                                                 | host cell attachment/invasion                                             | 8.95E-05                        | <2   |
| **TGME49_058550** SRS28 (SporoSG)                                       | host cell attachment/invasion                                             | 1.44E-14                        | 323  |
| **TGME49_058810** SRS27B                                                 | host cell attachment/invasion                                             | 4.84E-09                        | 153  |
| **TGME49_065120** hypothetical protein, conserved (RON2 iso2)           | moving junction formation                                                | 8.17E-08                        | 28   |
| **TGME49_094400** hypothetical protein (RON2 iso 1)                     | moving junction formation                                                | 4.98E-12                        | 16   |
| **TGME49_115730** apical membrane antigen, putative (AMA1 iso1)         | moving junction formation                                                | 9.89E-06                        | n.a. |
| **TGME49_065400** DNA photolyase, putative                              | DNA repair                                                               | 1.82E-10                        | 252  |
| **TGME49_016150** oligopeptidase F, putative                            | protein fate                                                             | 1.21E-11                        | 213  |
| **TGME49_031060** subtilase family serine protease, putative            | protein fate                                                             | 3.95E-07                        | <2   |
| **TGME49_034950** protein kinase (incomplete catalytic triad)           | protein fate                                                             | 2.22E-15                        | <2   |
| **TGME49_044620** NEK kinase                                            | protein fate                                                             | 1.11E-10                        | <2   |
| **TGME49_046800** acylamino-acid-releasing enzyme, putative              | protein fate                                                             | 2.10E-10                        | <2   |
| **TGME49_047240** ubiquitin carboxyl-terminal hydrolase isozyme L5, putative | deubiquitination pathway                                               | 7.70E-11                        | <2   |
| **TGME49_066780** protein kinase (incomplete catalytic triad)           | protein fate                                                             | 4.22E-14                        | <2   |
| **TGME49_089240** DnaJ domain-containing protein                        | protein fate                                                             | 4.52E-11                        | <2   |
| **TGME49_095640** endothelin-converting enzyme, putative                | protein fate                                                             | 3.79E-12                        | 3    |
| **TGME49_107640** CMGC kinase, CK2 family                              | protein fate                                                             | 2.15E-12                        | 140  |
| **TGVEG_058750** protein kinase domain-containing protein, putative    | protein fate                                                             | 8.47E-07                        | n.a. |
| **TGME49_065230** electron transfer flavoprotein-ubiquinone oxidoreductase, putative | protein fate                                                             | 1.13E-12                        | 8    |
| **TGME49_114330** ABC transporter, putative                             | protein fate                                                             | 9.50E-05                        | 31   |
| **TGME49_020300** ribosomal protein L15, putative                       | biogenesis of cellular components                                         | 9.08E-05                        | <2   |
| **TGME49_009920** PAN domain-containing protein                          | biogenesis of cellular components                                         | 2.33E-14                        | 557  |
| **TGME49_032400** PAN domain-containing protein                          | biogenesis of cellular components                                         | 7.77E-15                        | 44   |
| **TGME49_038460** SRS22B                                                 | biogenesis of cellular components                                         | 8.95E-05                        | <2   |
| **TGME49_058550** SRS28 (SporoSG)                                       | biogenesis of cellular components                                         | 1.44E-14                        | 323  |
| **TGME49_058810** SRS27B                                                 | biogenesis of cellular components                                         | 4.84E-09                        | 153  |
| **TGME49_065120** hypothetical protein, conserved (RON2 iso2)           | biogenesis of cellular components                                         | 8.17E-08                        | 28   |
| **TGME49_094400** hypothetical protein (RON2 iso 1)                     | biogenesis of cellular components                                         | 4.98E-12                        | 16   |
| **TGME49_115730** apical membrane antigen, putative (AMA1 iso1)         | biogenesis of cellular components                                         | 9.89E-06                        | n.a. |
| **TGME49_065400** DNA photolyase, putative                              | protein fate                                                             | 1.82E-10                        | 252  |
| **TGME49_016150** oligopeptidase F, putative                            | protein fate                                                             | 1.21E-11                        | 213  |
| **TGME49_031060** subtilase family serine protease, putative            | protein fate                                                             | 3.95E-07                        | <2   |
| **TGME49_034950** protein kinase (incomplete catalytic triad)           | protein fate                                                             | 2.22E-15                        | <2   |
| **TGME49_044620** NEK kinase                                            | protein fate                                                             | 1.11E-10                        | <2   |
| **TGME49_046800** acylamino-acid-releasing enzyme, putative              | protein fate                                                             | 2.10E-10                        | <2   |
| **TGME49_047240** ubiquitin carboxyl-terminal hydrolase isozyme L5, putative | deubiquitination pathway                                               | 7.70E-11                        | <2   |
| **TGME49_066780** protein kinase (incomplete catalytic triad)           | protein fate                                                             | 4.22E-14                        | <2   |
| **TGME49_089240** DnaJ domain-containing protein                        | protein fate                                                             | 4.52E-11                        | <2   |
| **TGME49_095640** endothelin-converting enzyme, putative                | protein fate                                                             | 3.79E-12                        | 3    |
| **TGME49_107640** CMGC kinase, CK2 family                              | protein fate                                                             | 2.15E-12                        | 140  |
| **TGVEG_058750** protein kinase domain-containing protein, putative    | protein fate                                                             | 8.47E-07                        | n.a. |
| **TGME49_065230** electron transfer flavoprotein-ubiquinone oxidoreductase, putative | protein fate                                                             | 1.13E-12                        | 8    |
| **TGME49_114330** ABC transporter, putative                             | protein fate                                                             | 9.50E-05                        | 31   |
| **TGME49_020300** ribosomal protein L15, putative                       | protein fate                                                             | 9.08E-05                        | <2   |
Table 1 List of putative oocyst/sporozoite-specific proteins (POSPs) identified in this study (Continued)

| Accession   | Description                                      | Annotation   | Precursor | Retention | Charge | MascotScore |
|-------------|--------------------------------------------------|--------------|-----------|-----------|--------|-------------|
| TGME49_043720 | peroxisomal biogenesis factor 11 domain-containing protein | -            | 15        | 22        | 20     | 1.25E-05    |
| TGME49_086250 | oocyst wall protein, putative (OWP6)             | -            | 44        | 7         | 12     | 6.83E-10    |

**other**

| Accession   | Description                                      | Annotation   | Precursor | Retention | Charge | MascotScore |
|-------------|--------------------------------------------------|--------------|-----------|-----------|--------|-------------|
| TGGT1_064840 | hypothetical protein                              | -            | n.a.      | n.a.      | 7.85E-08|
| TGGT1_071710 | hypothetical protein, conserved                  | -            | n.a.      | n.a.      | 5.11E-12|
| TGGT1_090830 | hypothetical protein, conserved                  | -            | n.a.      | n.a.      | 2.89E-05|
| TGGT1_099390 | hypothetical protein, conserved                  | -            | n.a.      | n.a.      | 7.99E-14|
| TGGT1_122010 | hypothetical protein, conserved                  | -            | n.a.      | n.a.      | 6.77E-14|
| TGGT1_122320 | hypothetical protein, conserved                  | -            | n.a.      | n.a.      | 4.09E-13|
| TGME49_002100 | hypothetical protein                             | -            | 847       | 425       | 583    | 1.36E-07    |
| TGME49_002110 | hypothetical protein                             | -            | 1163      | 321       | 751    | 7.05E-11    |
| TGME49_003230 | hypothetical protein                             | -            | 11        | 42        | 27     | 3.05E-09    |
| TGME49_003880 | hypothetical protein                             | -            | 29        | 150       | 77     | 1.80E-09    |
| TGME49_007250 | hypothetical protein                             | -            | 155       | 15        | 28     | 7.55E-07    |
| TGME49_009470 | hypothetical protein                             | -            | 476       | 63        | 155    | 7.17E-10    |
| TGME49_009810 | hypothetical protein                             | -            | <2        | 30        | 11     | 2.86E-12    |
| TGME49_012030 | hypothetical protein                             | -            | <2        | 9         | 5      | 8.40E-11    |
| TGME49_016970 | hypothetical protein, conserved                 | -            | –5        | 2         | <2     | 1.44E-14    |
| TGME49_020280 | SCP-like domain-containing protein               | -            | n.a.      | n.a.      | 1.00E-30|
| TGME49_023430 | hypothetical protein                             | -            | <2        | 66        | 6      | 1.23E-09    |
| TGME49_023830 | fasciclin domain-containing protein             | -            | n.a.      | n.a.      | 1.50E-08|
| TGME49_023900 | hypothetical protein                             | -            | 4         | <2        | <2     | 4.63E-05    |
| TGME49_025120 | rRNA processing protein, putative               | -            | n.a.      | n.a.      | 1.00E-09|
| TGME49_026230 | hypothetical protein                             | -            | <2        | 21        | 21     | 3.78E-08    |
| TGME49_028240 | hypothetical protein                             | -            | <2        | <2        | <2     | 2.11E-13    |
| TGME49_030530 | hypothetical protein                             | -            | 220       | 22        | 33     | 1.99E-10    |
| TGME49_030540 | hypothetical protein                             | -            | 53        | 6         | 10     | 4.33E-08    |
| TGME49_031390 | hypothetical protein                             | -            | 618       | 69        | 138    | 1.46E-09    |
| TGME49_037080 | hypothetical protein                             | -            | 1315      | 582       | 905    | 1.56E-10    |
| TGME49_038160 | hypothetical protein                             | -            | <2        | 252       | 78     | 1.03E-13    |
| TGME49_038910 | hypothetical protein                             | -            | n.a.      | n.a.      | 3.50E-05|
| TGME49_040610 | hypothetical protein, conserved                 | -            | 65        | 5         | 3      | 3.57E-08    |
| TGME49_044410 | hypothetical protein                             | -            | n.a.      | n.a.      | 1.67E-07|
| TGME49_048170 | hypothetical protein                             | -            | <2        | 4         | 2      | 3.33E-14    |
| TGME49_048230 | hypothetical protein                             | -            | <2        | <2        | <2     | 7.93E-05    |
| TGME49_054760 | hypothetical protein                             | -            | 153       | 126       | 80     | 1.12E-07    |
| TGME49_055380 | hypothetical protein                             | -            | 917       | 150       | 228    | 8.39E-12    |
| TGME49_057690 | hypothetical protein                             | -            | 16        | 3         | 3      | 2.10E-10    |
| TGME49_058200 | glutamic acid-rich protein, putative            | -            | <2        | 48        | 31     | 6.43E-09    |
| TGME49_058380 | hypothetical protein                             | -            | <2        | <2        | <2     | 6.17E-05    |
| TGME49_059670 | von Willebrand factor type A domain-containing protein | -            | <2        | 257       | 41     | 2.22E-15    |
| TGME49_062470 | beta antigen, putative                           | -            | 658       | 129       | 203    | 5.09E-05    |
| TGME49_065130 | hypothetical protein                             | -            | <2        | <2        | <2     | 3.30E-11    |
| TGME49_067980 | hypothetical protein                             | -            | <2        | 9         | 5      | 2.01E-07    |
| TGME49_068880 | hypothetical protein                             | -            | –19       | –3        | –4     | 3.51E-09    |
| TGME49_069350 | hypothetical protein                             | -            | <2        | <2        | <2     | 3.29E-11    |
Branched amino acid degradation

The analysis of the POSP subset revealed that also the degradation pathway of the branched amino acids valine, leucine and isoleucine, which represents an important source of acetyl-CoA, is more extensively covered in the oocyst than in the tachyzoite. Two POSPs mapping to this mitochondrial pathway correspond to enzymes specifically involved in leucine degradation, i.e., isovaleryl-CoA dehydrogenase (TGME49_005430; EC 1.3.99.10) and methylglutaconyl-CoA hydratase (TGME49_002140; EC 4.2.1.18), whereas a third enzyme, 2-methylbutyryl-CoA dehydrogenase (TGME49_066270), is common to the pathways leading to valine and isoleucine degradation and fatty acid β-oxidation.
Fatty acid metabolism
The POSPs include several enzymes implicated in fatty acid degradation, also known as β-oxidation. This important energy-producing process consists of successive rounds of four reactions each, during which one acetyl-CoA two-carbon unit is released at each cycle from even-chain fatty acids. The acetyl-CoA generated enters the TCA cycle, where it is further oxidized to fuel ATP synthesis via oxidative phosphorylation. The genome of *T. gondii* encodes all enzymes required for this process and six of them are represented in the POSP subset, i.e., two isoforms of acyl-CoA dehydrogenases (TGME49_047500, TGME49_115480; EC 1.3.3.6), 2-methylbutyryl-CoA dehydrogenase (TGME49_066270; EC 1.3.8.1), 2,3-enoyl-CoA hydratase (TGME49_042390; EC 4.2.1.17), 3-hydroxyacyl-CoA dehydrogenase (TGME49_034570; EC 1.1.1.35) and 2,4-dienoyl-CoA reductase (TGME49_026300; EC 1.3.1.34). Interestingly, four of these enzymes share the presence of a peroxisomal targeting signal, including TGME49_047500, TGME-49_042390 and TGME49_034570, which catalyse the first three reactions of the β-oxidation cycle, respectively, and TGME49_026300, which plays an auxiliary role in the degradation of unsaturated fatty acids in animal peroxisomes. Beside the peroxisomal TGME49_047500 mentioned above, two additional POSPs belong to the class of FAD-dependent acyl-CoA dehydrogenases involved in the first step of β-oxidation, i.e., TGME49_115480 and TGME-49_066270. The two enzymes lack obvious organelle targeting signals and show substrate preference for medium- and short-chain fatty acids, respectively. Overall, these results indicate that, unlike tachyzoites, *T. gondii* oocysts rely on fatty acid breakdown to fuel the TCA cycle through the production of acetyl-CoA. Furthermore, the profile of β-oxidation proteins identified strongly suggests that, like in mammals, also in *T. gondii* this process takes place in both the peroxisomes and the mitochondria, with the two compartments being presumably involved in the degradation of very long- and medium/short-chain fatty acids, respectively.

Amylopectin metabolism
Like other apicomplexan parasites forming environmentally resistant oocysts, e.g., *Eimeria* spp. and *Cryptosporidium* spp., *T. gondii* stores glucose in cytoplasmic granules of amylopectin, a polysaccharide consisting of long linear chains of glucose units linked by α-1,4-glycosidic bonds, with occasional α-1,6-glycosidic bonds providing a branching point [37]. While virtually absent in tachyzoites, amylopectin is abundant in unsporulated oocysts, sporozoites and bradyzoites [40], which use it as energy source. Amylopectin degradation in *T. gondii* depends on the phosphorylase TGME49_110670 (EC 2.4.1.1), identified by proteomics in both oocysts and tachyzoites, which liberates monomers of glucose-1-phosphate by cleaving α-1,4-glycosidic bonds up to four glucose residues from a branching point. At this stage, further glucose mobilization requires a debranching step, provided by glucanotransferase (EC 2.4.1.25) and glucosidase (EC 3.2.1.33) activities. The former transfers three glucose residues from a four-residue amylopectin branch to a nearby α-1,4 chain, whereas the second cleaves the remaining α-1,6 linkage, producing a glucose unit. These two activities are provided by bifunctional debranching enzymes in mammals and yeast and by two distinct enzymes in most bacteria. We found that *T. gondii* oocysts share with tachyzoites the bifunctional debranching enzyme TGME49_026910, but uniquely express a bacterial-like 4-α-glucanotransferase (TGME-49_071210), whose cognate microarray mRNA levels are 254-fold higher in day 4 oocysts than in tachyzoites. The stage-specific expression of this enzyme has the potential to increase the rate of amylopectin debranching and glucose mobilization, supporting the extraordinary oocyst’s energy demand associated with the sporulation process.

Purine metabolism
Two enzymes linked to purine metabolism were identified exclusively in the oocyst. The first is purine nucleoside phosphorylase (PNP) (TGME49_107030), which converts exogenously acquired inosine and guanosine into hypoxanthine and guanine, respectively, thus providing a source of nucleobases for the synthesis of purine nucleotides. In accordance with the strict dependence of *T. gondii* on external supplies of purine nucleobases and nucleosides, the expression of PNP is likely an adaptive response maximising the incorporation of purines salvaged from the host cell before oocyst shedding. The second enzyme related to purine metabolism is the bifunctional sulfite adenylyltransferase-adenylylsulfate kinase (TGME49_082230), which catalyses the fixation of inorganic sulfate into the sulfuryl group donor molecule 3’-phosphoadenylyl-sulfate.

Glycerophospholipid and vitamin metabolism
Two members of the POSP subset are related to glycerophospholipid metabolism. The first protein (TGME-49_010260) is a glycerol-3-phosphate dehydrogenase, one of the key enzymes of the glycerol phosphate shuttle system for the electron transport across the mitochondrial membrane. Interestingly, this molecule appears to be a stage-specific variant of TGME49_107570, a closely related form of glycerol-3-phosphate dehydrogenase expressed in tachyzoites and not identified in the present study. Likewise, TGME49_003570 is a putative glycerol-3-phosphate acyltransferase distantly related to a second form of the enzyme so far identified only in tachyzoites. Concerning vitamin biosynthesis, two enzymes lacking proteomic evidence in tachyzoites were identified, i.e., thiamin pyrophosphokinase (TGME49_015250), which converts host-derived...
thiamine into its metabolically active form vitamin B1, and the subunit 1 (TGME49_003720) of the enzyme complex vitamin K epoxide reductase, which is responsible for the production of the co-factor vitamin K hydroquinone.

**Cell rescue, defence and virulence**
This relatively heterogeneous functional category is well represented in the POSP subset and includes proteins implicated in host cell attachment/invasion (10), components of the parasite antioxidant system (2) and members of the LCCL family (5). Proteins of the attachment/invasion subgroup include the rhoptry kinase family [41] protein ROP28 and 3 members of the SRS superfamily [27], i.e., SRS22B, SRS27B and the major sporozoite surface antigen SRS28 (SporoSAG) [9]. Additionally, our analysis identified a thrombospondin-related (TGME49_023480) and 2 PAN domain-containing (TGME49_009920, TGME49_032400) proteins showing domain architectures resembling those of known micronemal adhesins of *T. gondii*. Interestingly, invasion-related POSPs include also paralogous versions of the mutually interacting MJ proteins AMA1 [42] and RON2 [43,44], denominated AMA1 iso1 (TGME49_115730), RON2 iso1 (TGME49_094400) and RON2 iso2 (TGME49_065120) [45]. Recently, a crystallographic analysis mapped the AMA1-binding site of RON2 to a C-terminal sequence comprised between two closely spaced transmembrane domains [46]. The alignment of this amino acid sequence with the equivalent regions of the RON2 paralogs (Figure 5) revealed a higher similarity to RON2 iso2 and the conservation in this protein of 4 amino acid residues crucial for AMA1-RON2 interaction. The co-expression of 2 AMA1 and 3 RON2 isoforms represents a very distinctive trait of sporozoites which, compared to tachyzoites, seem to have the potential to assemble different MJ types.

Previous studies [47,48] revealed the presence in *T. gondii* of an elaborated antioxidant network based on cytosolic, mitochondrial and apicoplast enzymes implicated in the detoxification of oxygen radicals. Our analysis identified 2 members of this network lacking tachyzoite proteomic evidence, i.e., the mitochondrial superoxide dismutase SOD3 (TGME49_116190) and a putative glutaredoxin (TGME49_027150). While the mRNA levels of the SOD3 gene are 470-fold higher in sporulated tachyzoites, the gene encoding glutaredoxin TGME49_027150 appears to be equally expressed in all stages.

The third class of molecules lacking proteomic evidence in the tachyzoite consists of five proteins (TGME49_005660, TGME49_064070, TGME49_056040, TGME49_067410 and TGME49_063410) belonging to the so-called LCCL family, which is exclusive, among protozoan parasites, of the apicomplexa. In *T. gondii* this group of multi-modular proteins is composed by 7 members containing one or more copies of the LCCL domain (F. Spano, unpublished). Although the function of this protein class in *T. gondii* remains unknown, there is evidence that the plasmodial orthologs have a sexual stage-specific expression and are involved in oocyst/sporozoite maturation [49].

**Proteins belonging to other MIPS functional categories**
Other functionally heterogeneous members of the POSP subset appear particularly relevant to oocyst biology. One example is the DNA photolyase TGME49_006400, an evolutionarily conserved enzyme that repairs DNA damage, i.e., pyrimidine dimers, caused by the exposure to ultraviolet light. The stage-specificity of this enzyme is consistent with the oocyst need to resist various environmental stresses, including ultraviolet radiation. Accordingly, the DNA photolyase transcript is 30–100 fold more abundant throughout oocyst maturation compared to tachyzoites and bradyzoites. Another protein strictly related to oocyst resistance is the oocyst wall protein 6 (TgOWP6; TGME49_086250). As we showed previously [10], TgOWP6 belongs to a family of seven structurally related cysteine-rich proteins named TgOWP1-7. Using specific antibodies, TgOWP1-3 were shown to be abundantly expressed in the oocyst wall of *T. gondii* [10], yet in the present study TgOWP6 was the only member of this protein class to be identified, probably reflecting difficulties in solubilizing TgOWPs’ monomers engaged in multimeric complexes.

**Discussion**
We reported herein on the identification by mass spectrometry of 1615 proteins expressed in the oocyst of *T. gondii*, a developmental stage which has been scarcely characterized at the molecular level, despite its fundamental role in disease transmission. The present work adds to a very recently published proteomic analysis of *T. gondii* oocysts of strain M4 [25]. Both studies employed 1-D gel electrophoresis LC MS-MS, yet they differed for the parasite strain analysed, i.e., VEG (genotype III) versus M4 (genotype II), for the modality of protein extraction and fractionation, and principally for the maturation stage of the oocyst samples, which consisted of partially or fully sporulated oocysts, respectively. While the presence in our sample of both unsporulated and sporulated oocysts hampered the association of protein expression with a well defined oocyst maturation stage, it enabled the proteomic sampling of a wider range of proteins, including those expressed exclusively, or more abundantly, prior to sporulation. Excluding the proteins identified with a single peptide in just one experiment, the VEG oocyst dataset exceeded that of strain M4 by 510 proteins, of which
Possenti et al. BMC Genomics 2013, 14:183
http://www.biomedcentral.com/1471-2164/14/183
Page 13 of 18

73 lacked proteomic evidence in the tachyzoite and were identified here for the first time.

Although the coverage of the oocyst proteome provided by our analysis could not be determined, the considerable size of the produced dataset offered a representative view of the protein complement expressed during oocyst development and sporozoite differentiation. One of the major implications of the present study was to shed light for the first time on the metabolic organization of the oocyst/sporozoite, unveiling stage-specific differences with respect to the extensively studied tachyzoite. Numerous metabolic routes were identified underlying the metabolism of a wide range of molecules, including lipids, carbohydrates, amino acids, nucleotides and vitamins. Consistent with the resolution limit inherent to a single-platform, global proteomic analysis and considering that protein expression levels may range across many orders of magnitude, several metabolic pathways were not entirely covered by our study. This implies that establishing the non functionality of a given metabolic route in the oocyst will require a higher number of identifications. Nevertheless, the absence from both VEG and M4 [25] datasets of the entire enzymatic complements specific of isoprenoids (8 enzymes) and shikimate (5 enzymes) biosynthesis suggests that in the oocyst these pathways may be markedly downregulated or missing.

We found that T. gondii oocysts possess the full complement of both glycolytic and TCA cycle enzymes, differing from tachyzoites for the expression of alternative isoenzymes of enolase (ENO1), citrate synthase and phospho-enolpyruvate carboxykinase, which connects the two pathways by fueling gluconeogenesis. The relative contribution of glycolysis and TCA cycle to energy production in T. gondii is still an open issue. Previous works compared the in vitro activity of select enzymes involved in either of the two pathways, highlighting stage-specific differences between tachyzoites and bradyzoites. Biochemical data revealed that in bradyzoites glycolysis largely predominates over the TCA cycle, suggesting that this latent parasite stage lacks a functional electron transport chain [50]. Conversely, tachyzoites rely on both pathways, with glycolysis playing a major role in extracellular parasites by supplying most of the energy required for gliding motility and invasion [51,52], whereas oxidative phosphorylation is important for ATP homeostasis in intracellular tachyzoites [53]. Importantly, there is evidence that in T. gondii and Plasmodium spp. the TCA cycle is not coupled to glycolysis, as the pyruvate dehydrogenase complex, which catalyses pyruvate conversion into acetyl-CoA, is not typically localized to the mitochondrion, but is specific to the apicoplast [54,55]. This striking feature raises the question as to how T. gondii generates the mitochondrial acetyl-CoA to be fed into the TCA cycle. Our proteomic data indicated a very plausible explanation, pointing to a major involvement of two acetyl-CoA-producing pathways alternative to glycolysis, i.e., the β-oxidation of fatty acids and the degradation of branched amino acids. In fact, we identified all enzymes of the fatty acid β-oxidation route and the majority of those involved in the catabolism of valine, leucine and isoleucine, with several enzymes of both pathways lacking proteomic evidence in tachyzoites. The stage-specific usage of these two mitochondrial pathways is consistent with the peculiar biology of the oocyst, which must undergo the energy-demanding process of sporulation and survive in the environment for prolonged periods, without a continuous supply of host-derived nutrients. As an alternative to fatty acid and branched amino acid degradation, intracellular tachyzoites presumably fuel the TCA cycle using the enzyme acetyl-CoA synthetase (TGME49_066640), which could produce acetyl-CoA from the acetate scavenged from host cell mitochondria recruited to the parasitophorous vacuole. Comparative genomic analysis showed that apicomplexan parasites exhibit markedly different patterns of amino acid auxotrophy, with T. gondii encoding a complement of enzymes for the synthesis of 12 out of 20 amino acids, as opposed to 6 in Plasmodium, 4 in Cryptosporidium and 3 in Theileria [56]. We provided proteomic evidence that the capacity of de novo amino acid biosynthesis is developmentally modulated in T. gondii, with oocysts showing a greater commitment than tachyzoites, a feature that is in accordance with the long-term permanence of the oocyst in the extracellular environment.

The vast majority of the protein identifications reported herein were corroborated by mRNA expression data, 94% of which were derived from microarray analysis of M4 oocysts collected at day 0, 4 or 10 of sporulation [34]. In the present study, we employed a heterogeneous preparation of

Figure 5 Amino acid sequence variability in the AMA1-binding site of RON2 paralogs. The amino acid sequence of the AMA1-binding site of TgRON2 (red bar) was aligned with the corresponding regions of TgRON2 iso1 (TGME49_094400) and TgRON2 iso2 (TGME49_065120). The C-terminal transmembrane domains (TMD2 and TMD3) of the three paralogs are highlighted in grey. Conserved amino acids within the AMA1-binding sequence are framed in black, those lying in the flanking regions are bolded. Asterisks indicate RON2 amino acid residues playing a crucial role in AMA1 binding [46].
oocysts at various maturation stages, therefore a complete comparison between VEG proteomic and M4 microarray results was not feasible. However, 62 out of 1304 (4.7%) VEG proteins were encoded by genes not exceeding the 25th microarray percentile in M4 oocysts at all three sporulation time points. This evidence indicates that in our study a significant, and probably underestimated, proportion of proteins was successfully identified despite cognate mRNA levels close to baseline. Regarding the POSP subset, we found that of 134 proteins supported by microarray evidence in strain M4, approximately 30% were either associated with mRNA levels differing by less than 2-fold between oocysts and tachyzoites (9.7%) or encoded by transcripts whose relative abundance in tachyzoites was elevated, being comprised between the 50th and the 100th percentile (20.8%). These data are in evident contrast with the absence of these proteins from the extensively covered proteome expressed by the tachyzoite [32] and argue for the existence of T. gondii of post-transcriptional control mechanisms of protein expression, as already reported in other protozoan parasites [57-59]. In accordance with this hypothesis, we have previously shown that the genes TgOWP1, TgOWP2 and TgOWP3 are transcribed in both VEG oocysts and tachyzoites, yet the encoded oocyst wall proteins are not expressed in the latters [10]. Sequence analysis of RT-PCR products showed that tachyzoites differed from the oocyst for the presence of multiple mRNA forms of TgOWP1-3 in which one or more introns were retained, abolishing the coding potential of the immature transcripts. The same phenomenon was observed also for the SporoSAG gene (F. Spano, unpublished), pointing to the inhibition of pre-mRNA splicing as one of the strategies underlying stage-specific protein expression in T. gondii.

The molecular bases of host cell invasion by the sporozoite of T. gondii are virtually unknown, mostly due to the difficulty of preparation and the transitory nature of this infectious stage, which rapidly differentiates into a tachyzoite inside the host cell. It can be reasonably assumed that sporozoites and tachyzoites utilize the same invasion machinery, yet there is evidence that the former expresses stage-specific invasion-related proteins [9,25], exemplified here by SRS22B, SRS27B, SRS28, ROP28 and by isoforms of AMA1 and RON2. In addition, two of the POSPs identified, TGME49_032400 and TGME49_009920 [60], are valid MIC candidates, as they both possess a leader peptide followed by tandem copies of the PAN domain, previously described in the microneme proteins TgMIC4 of T. gondii [61] and EtMIC5 of Eimeria tenella [62]. Finally, it cannot be excluded that the POSP subset contains other invasion-related proteins, whose identification may be hampered by the low degree of phylogenetic conservation typical of ROPs and GRAs.

Conclusions
We have described the results of a global proteomic analysis of the oocyst/sporozoite of Toxoplasma gondii, expanding significantly the coverage of the protein repertoire expressed by this important parasite stage. Using partially sporulated oocysts of the genotype III strain VEG, we generated a dataset of 1304 non redundant proteins, accounting for ~18% of the total predicted proteome. Approximately 38% of the identifications corresponded to hypothetical proteins, whereas ~59% were classified according to the MIPS functional catalogue database. Importantly, we identified 154 proteins lacking proteomic evidence in the extensively studied tachyzoite stage, which are likely to represent oocyst/sporozoite-specific proteins (POSPs). Their functional profile reflects the adaptation of the oocyst of T. gondii to the nutrient-poor and stressing extracellular environment, as shown by the preponderance of enzymes involved in metabolism (28) and energy production (12) or by the presence of a photolyase DNA repair enzyme. Compared to tachyzoites, oocysts were found to have a greater capability of de novo amino acid biosynthesis and to rely on the degradation of fatty acids and branched amino acids as sources of acetyl-CoA. In addition, our data indicated that T. gondii sporozoites and tachyzoites possess extensively overlapping repertoires of invasion-related proteins, yet sporozoites express stage-specific isoforms of AMA1 and RON2, two proteins essential for moving junction formation and host cell invasion. Finally, the comparison between proteomic and microarray data showed that the stage-specific expression of a significant fraction of the POSPs cannot be justified by different mRNA levels in oocysts and tachyzoites, suggesting the existence of post-transcriptional control mechanisms. The present work shed light for the first time on the metabolic organization of the oocyst of T. gondii and represents a further step toward the understanding of the fundamental biology of this important parasite stage. A major goal of future proteomic studies should be the elucidation of proteome dynamics during oocyst transition from the unsporulated to the metabolically active, sporulating state, until the development of infectious, metabolically quiescent, sporozoites.

Methods
Parasites
Toxoplasma gondii oocysts of the VEG strain (genotype III) were recovered from the feces of experimentally infected cats housed at the United States Department of Agriculture Laboratory, Beltsville, Maryland as described [63]. All cats used in experiments were handled using procedures approved by the Beltsville Area Animal Care and Use Committee, United States Department of Agriculture, USA. Sporulation was induced by incubating the oocysts in 2% sulfuric acid at room temperature for one
week, successively keeping the parasites in the same solution at 4°C for prolonged storage. Oocysts were purified by sucrose floatation as described previously [1] and successively stored in 2% sulfuric acid. Tachyzoites of the VEG strain were cultured in human foreskin fibroblasts (HFF) in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% Nu-Serum (Gibco), 2 mM glutamine, 10 mM HEPES (N-2-hydroxyethylpiperazine N’-2-ethanesulfonic acid) and 20 μg/ml gentamicin.

Protein extraction
Purified *T. gondii* oocysts were treated with 10% sodium hypochlorite for 20 min on ice, extensively washed with PBS and ruptured by shaking on a vortex with 400–600 μm glass beads (Sigma) for 5 min, to obtain free sporocysts. Sporozoite excystation was induced by incubating the broken oocysts with 1.5% sodium taurocholate at 37°C for 40 min. Following PBS washings, the parasite material was collected by centrifugation at 10000 g for 10 min and further processed for protein extraction. To produce total protein lysates (experiments 1 and 2), the parasite pellet was resuspended in urea/thiourea buffer (7 M urea, 2 M thiourea, 2% CHAPS, 1% ASB 1–14, 1% SB 1–12), freeze-thawed three times, supplemented with 200 mM DTT/1% SDS and shaken at 900 rpm for 3 h at 37°C. Following centrifugation at 16000 g for 30 min at 4°C, the supernatant was recovered and analysed by 1D gel electrophoresis LC MS/MS. To produce fractionated lysates (experiment 3), the parasite pellet was resuspended in 100 mM Tris–HCl pH 8.5, supplemented with protease inhibitors and 200 mM DTT. The sample was freeze–thawed three times, subjected to three cycles of 5 min in a water bath sonicator and centrifuged at 16000 g for 30 min at 4°C, prior to collection of the supernatant. The pellet was washed three times with 100 mM Tris–HCl pH 8.5, containing protease inhibitors, and the washings were pooled with the supernatant constituting the soluble fraction. Next, the pellet was resuspended in urea/thiourea buffer, freeze-thawed three times, supplemented with 100 mM DTT/2% SDS, subjected to three cycles of 5 min in a water bath sonicator and incubated for 2 h at 37°C with shaking at 900 rpm. Following centrifugation at 16000 g for 30 min at 4°C, the supernatant, representing the insoluble fraction, was collected and analysed by 1D gel electrophoresis LC MS/MS along with the soluble fraction. Tachyzoite proteins were extracted in urea/thiourea buffer as mentioned above, starting from VEG parasites released from infected HFF by passage through a 27-gauge syringe needle and subsequently filtered through 3-μm pore diameter filters.

SDS-PAGE and in-gel digestion
From 50 to 75 μg of total protein extracts or soluble/insoluble protein fractions obtained from *T. gondii* oocysts were resolved by SDS-PAGE on 10% precast minigels (NuPAGE Novex Bis-Tris; Invitrogen), loading the samples in 1.2 cm-wide wells. Following staining with NuPage Colloidal Coomassie (Invitrogen), gel lanes were cut into 30 to 48 slices depending on protein band density. In-gel tryptic digestion was performed as previously described [64]. Briefly, gel slices were destained by washings in acetonitrile (ACN)/25 mM NH4CO3 (vol/vol), treated with 10 mM DTT (40 min at 56°C) and 55 mM iodoacetamide (30 min in the dark at RT) to reduce and alkylate cysteines, shrunken with ACN and rehydrated for 40 min on ice with a solution of 12.5 ng/μl trypsin (Promega) in 50 mM NH4CO3. Next, the trypsin solution was replaced with 25 mM NH4CO3 and protein digestion was carried out overnight at 37°C. Supernatants from individual gel slices were directly used for LC-MS/MS analysis.

Liquid chromatography tandem mass spectrometry
Analysis by LC-MS/MS was performed using a nano-HPLC 3000 Ultimate (Dionex) connected in line to LTQ-XL linear ion trap (Thermo Fisher). Tryptic digests (20 μl) were firstly loaded on a C18 RP-precolumn (300 μm i.d.×5 mm; 5 μm particle size; 100 Å pore size; LC Packings-Dionex) and washed by the loading pump at 20 μl/min with buffer A (95% ACN, 0.1% FA) for 5 min and then by the micro pump at 0.3 μl/min on an homemade 10 cm × 75 μm-i.d. Silica PicoTip (8 ±1 μm) column (PicoTip Emitter, NewObjective) packed with Magic C18AQ (5 μm particle size; 200 Å pore size, Michrom Bioresources Inc.) for chromatographic separations. Peptides were eluted along a 50 min linear gradient from 4% to 50% of buffer B (95% ACN, 0.1% FA) and electrosprayed directly into the mass spectrometer with a spray voltage of 1.65-1.75 kV and a capillary temperature of 180°C.

Data acquisition was performed in data-dependent mode to automatically switch between MS and MS2. Full-scan MS parameters settings was: automatic gain control value of 30000 ions; maximum injection time of 50 ms; m/z 400–2000 mass range. The five most intense ions were sequentially selected and fragmented in CID mode with the following parameters settings: isolation width of 2.0; automatic gain control value of 10000 ions; maximum injection time of 100 ms; m/z 50–2000 mass range; collision energy of 35%; minimum signal threshold of 200 counts; wide band activation on. A dynamic exclusion of ions previously sequenced within 30 sec was applied.

Mass spectrometry data processing
Raw spectra were analysed by Bioworks Browser 3.3.1 using the Sequest 3.1 search engine against an indexed database containing all predicted tryptic peptides from *T. gondii* proteins (ToxoDB release 5.1) [65]. Carbamidomethylation of cysteines was specified as fixed modification and oxidation
of methionine was set as variable modifications; mass tolerance was set to 1 Da for precursor ion and ±0.4 Da for fragment ions and a maximum of two missed cleavages was allowed. The minima criteria for protein identification were: peptide probability <1E-04; peptide XCorr vs charge = 1.5 for charge +1; 2 for charge +2; 2.5 for charge +3; 3 for charge +3; FDR <1%.

Bioinformatics predictions
All proteins identified were assigned a subcellular localization combining the results of the general predictor WoLF PSORT (http://wolfpsort.org/) with those obtained with the softwares PlaMiT (http://gecco.org.chemie.uni-frankfurt.de/plasmit/index.html), PATS (http://gecco.org.chemie.uni-frankfurt.de/pats/pats-index.php) and PTS1 (http://mendel.imp.ac.at/mendeljsp/sat/pts1/) for the identification of mitochondrial, apicoplast and peroxisomal targeting signals, respectively. Proteins were classified into functional categories according to the MIPS functional catalogue database (http://mips.helmholtz-muenchen.de/proj/functionDB/search_main_frame.html) based on GO biological process annotations provided by ToxoDB, on KEGG Pathway database (http://www.genome.jp/kegg/) annotations and on BLASTP homology searches (http://blast.ncbi.nlm.nih.gov/).

Production of recombinant proteins and western blot analysis
Recombinant fragments of the LCCL domain-containing proteins TGME49_056040 (amino acids 555–996) and TGME49_067410 (amino acids 353–682) and of the tyrosine-rich protein TGME49_119890 (amino acids 24–193) were produced in Escherichia coli (strain M15) as fusion products with an N-terminal tag of six histidines using the expression plasmid pQE30 (Qiagen). The following primers were used for PCR amplification of the target sequences from a T. gondii cDNA library of partially sporulated oocysts provided by Michael White (Montana State University): 056040F (5’-GATCTGGATCCGGCAACGCC TACGCTGACTGCT-3’), 056040R (5’-GTAGACTGCA GTTACGCAACTCTGTCAGAAATCTTT-3’); 067410F (5’-AGTCAAGGATCCGTAGCTATTTGGATATGCTGC A-3’), 067410R (5’-AGTCACAAGTTTTCATGCCAT ATCTTCCTGGTACTGG-3’); 119890F (5’-ATCTG GATCCGAGACTGAGGGGCGCAAGTT-3’), 119890R (5’-AGATAGGCTTTTATCCACCGAAAAGATTGGCGCA G-3’). The recombinant polypeptides were purified from total bacterial lysates by nickel affinity chromatography under denaturing conditions and successively dialysed against multiple changes of PBS, pH 7.2. To raise mouse antisera by intraperitoneal injection, BALB/c female mice were immunized three times (at 3–4 week intervals) with 50 μg of purified recombinant protein in complete (first immunization) or incomplete (first boost) Freund’s adjuvant. Individual sera were collected 2 weeks after the second boost (soluble antigen in PBS). The animal work has been authorized by the Italian Ministry of Health, according to the Legislative Decree 116/92 which implemented the European Directive 86/609/EEC on laboratory animal protection. Animals used in this study were housed at the Istituto Superiore di Sanità and treated according to Legislative Decree 116/92 guidelines.

Total protein extracts from VEG oocysts and tachyzoites were quantified with a Qubit fluorometer (Invitrogen) and equal amounts of the two samples were resolved by SDS–PAGE on 10% NuPage Novex Bis–Tris gels (Invitrogen). Following transfer to nitrocellulose, the blots were blocked with 5% w/v skimmed milk in 1X Tris Borate Saline Tween (TBST; 50 mM Tris pH 8.0, 150 mM NaCl, 1% Tween 20) and probed for 1 h with the appropriate mouse antiserum (1:1000) or with the anti-SAG1 mAb T41E5 (1:20000), kindly donated by J-F. Dubremetz, (University of Montpellier, France). After 30 min incubation with a goat anti-mouse IgG secondary antibody conjugated to horseradish peroxidase (BioRad), reactive protein bands were revealed by chemiluminescence with LiteAblot Plus (EuroClone, Italy).

Additional files

Additional file 1: Figure S1. Electrophoretic profiles of fractionated oocyst/sporozoite proteins of T. gondii. In experiment 3, Tris-soluble and Tris-insoluble protein samples were resolved by SDS-PAGE on a 10% acrylamide gel under reducing conditions and processed for LC-MS/MS analysis. Protein bands were visualized by staining with colloidal Coomassie. The arrows indicate the positions of representative gel slices.

Additional file 2: Table S1. Complete dataset of T. gondii oocyst/ sporozoite proteins identified in this study. The table includes the list of the 1615 VEG oocyst proteins identified in the present study. Each protein is identified by the gene ID (column A) and annotation (column B) provided by ToxoDB 7.1. Columns C-E report Bioworks Browser 3.3.1 parameters, the number of peptides indicated in column F refers to the best identification. Column F reports the number of experiments in which each protein was identified. Column G indicates the predicted molecular weight of full length polypeptides. Asterisks indicate two proteins (TGGT1_064110 and TGGT1_064850) identified with a single peptide shared by other T. gondii proteins, whose IDs and annotations are reported at the bottom of the table.

Abbreviations
AO: Acetonitrile; DTT: Dithiothreitol; CoA: Coenzyme A; EST: Expressed Sequence Tag; GO: Gene Ontology; KEGG: Kyoto Encyclopedia of Genes and Genomes; LC-MS/MS: Liquid Chromatography Tandem Mass Spectrometry; L- DOPA: 3,4-Dihydroxy-L-Phenylalanine; MJ: Moving Junction; mRNA: messenger RNA; SDS: Sodium Dodecyl Sulfate; TqOWP: Toxoplasma gondii Oocyst: Wall Protein; POSP: Putative Oocyst/Sporozoite-Specific Protein; RON: Rhoptry Neck Protein; SAGE: Serial Analysis of Gene Expression; TBST: Tris Borate Saline Tween; TCA: Tricarboxylic Acid.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
FS conceived the study, carried out data analysis and bioinformatic predictions. MP conceived the study, carried out data analysis and critically revised the study, carried out data analysis and critically revised the manuscript. E. Pizzi carried out data analysis and bioinformatic predictions. MP conceived the study, analysed and interpreted the data and wrote the manuscript.
Received: 25 June 2012 Accepted: 7 March 2013

References

1. Dubey JP. Toxoplasmosis of animals and humans. 2nd edition. Boca Raton, Florida: CRC Press; 2009.
2. Remington JS, Mc Leod R, Thulliez P, Desmonts G: Toxoplasmosis. 6th edition. Philadelphia, Pennsylvania: Saunders, W.B., 2005.
3. Jones LA, Alexander J, Roberts CV: Ocular toxoplasmosis: in the storm of the eye. Parasite Immunol 2006, 28(12):635–642.
4. Dubey JP, Lindsay DS, Speer CA: Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin Microbiol Rev 1998, 11(2):267–299.
5. Belli S, Smith NC, Ferguson DJ: The coccidial oocyst: a tough nut to crack! Trends Parasitol 2006, 22(8):416–425.
6. Ferguson DJ, Birch-Anderson A, Hutchison WM, Siim JC: Ultrastructural studies on the endogenous development of Eimeria brunetti II. Microgametogyne and the microgamete. Acta Pathol Microbiol Scand B 1977, 85B:167–77.
7. Kasper LH: Identification of stage-specific antigens of Toxoplasma gondii. Infect Immun 1989, 57(3):668–672.
8. Kasper LH, Ware PJ: Recognition and characterization of stage-specific oocyst/sporozoite antigens of Toxoplasma gondii by human antisera. J Clin Invest 1985, 75(5):1570–1577.
9. Radke JR, Gubbels MJ, Jerome ME, Radke JB, Striepen B, White MW: Identification of a sporozoite-specific member of the Toxoplasma SAG superfamily via genetic complementation. Mol Microbiol 2004, 52(1):93–105.
10. Possenti A, Chenki S, Bertuccini L, Pozzi E, Dubey JP, Spano F: Molecular characterisation of a novel family of cytotoxic-rich proteins of Toxoplasma gondii and ultrastructural evidence of oocyst wall localisation. Int J Parasitol 2010, 40(12):1639–1649.
11. Hill D, Coss C, Dubey JP, Wodblevski K, Saattur M, Hosten T, Munoz-Zanari C, Mui E, Withers S, Boyer K et al: Identification of a sporozoite-specific antigen from Toxoplasma gondii. J Parasitol 2011, 97(2):328–337.
12. Cohen AM, Rumpek K, Coombs GH, Wastling JM: Characterisation of global protein expression by two-dimensional electrophoresis and mass spectrometry: proteomics of Toxoplasma gondii. Int J Parasitol 2002, 32(1):39–51.
13. Xia D, Sanderson SJ, Jones AR, Prieto JH, Yates JR, Bromley E, Tornley FM, Lal K, Sinde RE, Brunk BV, et al: The proteome of Toxoplasma gondii: integration with the genome provides novel insights into gene expression and annotation. Genome Biol 2008, 9(7):R116.
14. Bradley PJ, Ward C, Cheng SJ, Alexander DL, Coller S, Coombs GH, Dunn JD, Ferguson DJ, Sanderson SJ, Wastling JM, et al: Proteomic analysis of rhytaphygen organelles reveals many novel constituents for host-parasite interactions in Toxoplasma gondii. J Biol Chem 2005, 280(40):34245–34258.

15. Zhou XW, Kafack BF, Cole RN, Beckett P, Shen RF, Camathias V: The opportunistic pathogen Toxoplasma gondii deploys a diverse legion of invasion and survival proteins. J Biol Chem 2005, 280(40):34233–34244.
16. Che FY, Madrid-Altice C, Burd B, Zhang H, Newes E, Kim K, Fiser A, Angeletti RH, Weiss LM: Comprehensive proteomic analysis of membrane proteins in Toxoplasma gondii. Mol Cell Proteomics 2011, 10(11):M110 000745.
17. Luo Q, Upadhyay R, Zhang H, Madrid-Altice C, Newes E, Kim K, Angeletti RH, Weiss LM: Analysis of the glycoproteome of Toxoplasma gondii using lectin affinity chromatography and tandem mass spectrometry. Microbes Infect 2011, 13(14–15):1199–1210.
18. Nebi T, Prieto JH, Kapp E, Smith BJ, Williams MJ, Yates JR 3rd, Cowman AF, Tonkin CJ: Quantitative in vivo analyses reveal calcium-dependent phosphorylation sites and identifies a novel component of the Toxoplasma invasion complex. PLoS Pathog 2011, 7(10):e1002222.
19. Treece M, Sanders JL, Elias JE, Boothroyd JC: The phosphoproteomes of plasmodium falciparum and Toxoplasma gondii reveal unusual adaptations within and beyond the parasites’ boundaries. Cell Host Microbe 2011, 10(4):410–419.
20. Hu K, Johnson J, Florens L, Frauenholz M, Suravajala S, Dilullo C, Yates J, Roos DS, Murray JM: Cytoskeletal components of an invasion machine—the apical complex of Toxoplasma gondii. PLoS Pathog 2006, 2(2):e13.
21. Kawase O, Nishikawa Y, Bannai H, Zhang H, Zhang G, Jin S, Lee EG, Xu X: Proteomic analysis of calcium-dependent secretion in Toxoplasma gondii. Proteomics 2007, 7(12):3718–3725.
22. Snelling WJ, Lin Q, Moore J, Millar BC, Tosini F, Pozzi E, Dooley JS, Lowery CJ: Proteomics analysis and protein expression during sporozoite excystation of Cryptosporidium parvum (coccidia, apicomplexa). Mol Cell Proteomics 2007, 6(3):436–455.
23. Sanderson SJ, Xia D, Prieto H, Yates J, Heiges M, Kissinger JC, Bromley E, Lal K, Reid AJ, Vermont SJ, Cotton JA, Harris D, Hill-Cawthorne GA, Konen-Waisman S, Latham SM, Mourier T, Norton R, Quail MA, et al: Comparative genomics of the apicomplexan parasites Toxoplasma gondii and Neospora caninum: coccidia differing in host range and transmission strategy. PLoS Pathog 2012, 8(7):e1002557.
24. Jung C, Lee CY, Grigg ME: The SRS superfamily of Toxoplasma surface proteins. Int J Parasitol 2004, 34(3):285–296.
25. Boothroyd JC, Dubey J, Kapp E, and the dual roles of Toxoplasma rhoptry. Nat Rev Microbiol 2008, 6(1):79–88.
26. Braseiro S, Michelin A, Pinzet J, Dubemot JF, Lebrun M: Export of a Toxoplasma gondii rhoptry complex protein to the host cell membrane to form the moving junction during invasion. PLoS Pathog 2009, 5(2):e1000399.
27. Alexander DL, Mital J, Ward GE, Bradley P, Boothroyd JC: Identification of the moving junction complex of Toxoplasma gondii: a collaboration between distinct secretory organelles. PLoS Pathog 2005, 1(2):e17.
28. Mercer C, Adjilodge KD, Daubener W, Delawau MF: Dense granules: are they key organelles to help understand the parasitophorous vacuole of all apicomplexa parasites? Int J Parasitol 2002, 32(13):829–849.
29. Wastling JM, Xia D, Schal A, Chaussepied M, Pain A, Langley G: Proteomes and transcriptomes of the apicomplexa—where’s the message? Int J Parasitol 2009, 39(2):135–143.
30. Radke JR, Behnke MS, Mackey AJ, Radke JB, Roos DS, White MW: The transcriptome of Toxoplasma gondii. BMC Biol 2005, 3:26.
31. Fritz HM, Buchholz KR, Chen X, Dutnall-Johnson B, Roeke DM, Conrad PA, Boothroyd JC: Transcriptomic analysis of Toxoplasma development reveals many novel functions and structures specific to sporozoites and oocysts. PLoS One 2012, 7(2):e39998.
32. Paredes-Santos TC, de Souza W, Attias M: Dynamics and 3D organization of secretory organelles of Toxoplasma gondii. J Struct Biol 2012, 177(2):420–430.
36. Dzierszinski F, Mortuaine M, Dendouga N, Popescu O, Tomavo S: Differential expression of two plant-like enolases with distinct enzymatic and antigenic properties during stage conversion of the protozoan parasite *Toxoplasma gondii*. J Mol Biol 2001, 309(5):1017–1027.

37. Coppin A, Dzierszinski F, Legrand S, Mortuaine M, Ferguson D, Tomavo S: Developmentally regulated biosynthesis of carbohydrate and storage polysaccharide during differentiation and tissue cyst formation in *Toxoplasma gondii*. Biochimie 2003, 85(3):353–361.

38. Gaskell EA, Smith JE, Pinney JW, Westhead DR, McGonkey GA: A unique dual activity amino acid hydroxylase in *Toxoplasma gondii*. PLoS One 2009, 4(3):e4801.

39. Belli S, Wallach MG, Luxford C, Davies MJ, Smith NC: Roles of tyrosine-rich precursor glycoproteins and dityrosine- and 3,4-dihydroxyphenylalanine-mediated protein cross-linking in development of the oocyst wall in the coccidian parasite *Eimeria maxima*. Eukaryot Cell 2003, 2(3):456–464.

40. Speer CA, Clark S, Dubey JP: Ultrastructure of the oocysts, sporocysts, and sporozoites of *Toxoplasma gondii*. J Parasitol 1998, 84(3):505–512.

41. El Hajj H, Demey E, Poncet J, Lebrun M, Wu B, Galeotti N, Fourmaux MN, Mercereau-Pujal A, Vial H, Labesie G, et al: The ROP2 family of *Toxoplasma gondii* rhoptry proteins: proteomic and genomic characterization and molecular modeling. Proteomics 2006, 6(21):5773–5784.

42. Tyler JS, Treed M, Boothroyd JC: Focus on the ringleader: the role of AMA1 in apicomplexan invasion and replication. Trends Parasitol 2011, 27(9):410–420.

43. Tyler JS, Boothroyd JC: The C-terminus of *Toxoplasma gondii* RON2 provides the crucial link between AMA1 and the host-associated invasion complex. PLoS Pathog 2011, 7(2):e1001282.

44. Lamanque M, Besteiro S, Papon J, Roques M, Vuliez-Le Normand B, Morlon-Guyot J, Dubremetz JF, Aichouy S, Tornavon N, Faber BW, et al: The RON2-AMA1 interaction is a critical step in moving junction-dependent invasion by apicomplexan parasites. PLoS Pathog 2011, 7(2):e1001276.

45. Besteiro S, Dubremetz JF, Lebrun M: The moving junction of apicomplexan parasites: a key structure for invasion. Cell Microbiol 2011, 13(6):797–805.

46. Tonkin ML, Roques M, Lamanque MH, Pugnere M, Douquet D, Crawford J, Lebrun M, Boulanger MJ: Host cell invasion by apicomplexan parasites: insights from the co-structure of AMA1 with a RON2 peptide. Science 2011, 333(6041):463–467.

47. Ding M, Kwok LY, Schluter D, Clayton Y, Solari AJ, Perron AJ: The antioxidant systems in *Toxoplasma gondii* and the role of cystolic catalase in defence against oxidative injury. Mol Microbiol 2004, 51(1):47–57.

48. Pino P, Fath BJ, Kwok LY, Sheiner L, Schepers R, Solari AJ, Fordow J, Lebrun M, Boulanger MJ: Host cell invasion by apicomplexan parasites: insights from the co-structure of AMA1 with a RON2 peptide. Science 2011, 333(6041):463–467.

49. Lamanque M, Besteiro S, Papon J, Roques M, Vuliez-Le Normand B, Morlon-Guyot J, Dubremetz JF, Aichouy S, Tornavon N, Faber BW, et al: The RON2-AMA1 interaction is a critical step in moving junction-dependent invasion by apicomplexan parasites. PLoS Pathog 2011, 7(2):e1001276.

50. Denton H, Roberts CW, Alexander J, Thong KW, Coombs GH: Enzymes of energy metabolism in the bradyzoites and tachyzoites of *Toxoplasma gondii*. J Biol Chem 2004, 279(11):102–108.

51. Denton H, Roberts CW, Alexander J, Thong KW, Coombs GH: Enzymes of energy metabolism in the bradyzoites and tachyzoites of *Toxoplasma gondii*. J Biol Chem 2004, 279(11):102–108.

52. Denton H, Roberts CW, Alexander J, Thong KW, Coombs GH: Enzymes of energy metabolism in the bradyzoites and tachyzoites of *Toxoplasma gondii*. J Biol Chem 2004, 279(11):102–108.

53. Lin SS, Gross U, Bohn W: Type II NADH dehydrogenase inhibitor 1-hydroxy-2,3-dodecyl-4H-quinolone leads to collapse of mitochondrial inner-membrane potential and ATP depletion in *Toxoplasma gondii*. Eukaryot Cell 2009, 8(6):877–887.

54. Fleige T, Fischer K, Ferguson DJ, Gross U, Bohn W: Carbohydrate metabolism in the *Toxoplasma gondii* apicoplast: localization of three glycolytic isoenzymes, the single pyruvate dehydrogenase complex, and a plastid phosphate translocator. Eukaryot Cell 2007, 6(6):984–996.

55. Fath BJ, Stimmmer LM, Handman E, Crabb BS, Hodder AH, McFadden GI: The malaria parasite *Plasmodium falciparum* has only one pyruvate dehydrogenase complex, which is located in the apicoplast. Mol Microbiol 2005, 55(1):39–53.

56. Chaudhary K, Roos DS: Protozoan genomics for drug discovery. Nat Biotechnol 2005, 23(9):1089–1091.

57. Li W, Sanyai AA, Wang CC: The profile of snRNA-derived microRNAs that regulate expression of variant surface proteins in giardia lambia. Cell Microbiol 2012, 14(9):1455–73.

58. Quijada L, Soto M, Alonso C, Requena JM: Analysis of post-transcriptional regulation operating on transcription products of the tandemly linked *Leishmania infantum* hsp70 genes. J Biol Chem 1997, 272(7):4493–4499.

59. Hall N, Karras M, Raine JD, Carlton JM, Kool TW, Beriman M, Flores L, Janssen CS, Pain A, Christophides GK, et al: A comprehensive survey of the *Plasmodium* life cycle by genomic, transcriptomic, and proteomic analyses. Science 2005, 307(5716):82–86.

60. Geng H, Kobayashi K, Sugi T, Takemae H, Kurokawa H, Horimoto T, Akashi H, Kato K: A novel PAN/Apple domain-containing protein from *Toxoplasma gondii*: characterization and receptor identification. PLoS One 2012, 7(1):e30169.

61. Brecht S, Caruthers VB, Ferguson DJ, Giddings OK, Wang G, Jakle U, Harper JM, Sibley LD, Soldati D: The *Toxoplasma* microneme protein MIC4 is an adhesin composed of six conserved apple domains. J Biochem 2001, 276(6):4119–4127.

62. Dubey JP, Lunney JK, Shen SK, Kwok OC, Ashford DA, Thulliez P: Infectivity of low numbers of *Toxoplasma gondii* oocysts to pigs. J Parasitol 1996, 82(3):438–443.

63. Di Cioloano F, Raggi C, Binago C, Pizzi E, Lalle M, Picci L, Pace T, Bachi A, de Jong J, Janse CJ, et al: *Plasmodium* lipid rafts contain proteins implicated in vesicular trafficking and signalling as well as members of the PIR superfamily, potentially implicated in host immune system interactions. Proteomics 2008, 8(12):2500–2513.

64. Gajria B, Bahl A, Brestelli J, Dommor J, Fischer S, Gao X, Heiges M, Iodice J, Kissinger JC, Mackey AJ, et al: Toxodb: an integrated *Toxoplasma gondii* database resource. Nucleic Acids Res 2008, 36(Database issue):D553–556.